Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Soft Tissue Sarcoma (STS): early-phase trial registry

1 of 1 indexed Soft Tissue Sarcoma (STS) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Soft Tissue Sarcoma (STS): 1 US clinical trial tracked, 1 recruiting.

Soft Tissue Sarcoma (STS) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is GI Innovation, running 1 of these trials.

Enrollment posture brief

Registry condition soft-tissue-sarcoma-sts

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Soft Tissue Sarcoma (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Soft Tissue Sarcoma (STS)

Soft Tissue Sarcoma (STS) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Soft Tissue Sarcoma (STS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Soft Tissue Sarcoma (STS) is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

GI Innovation 1 trials

Named interventions

Most-linked intervention names on Soft Tissue Sarcoma (STS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

paclitaxel Drug
1 trials
doxorubicin Drug
1 trials
GI-102 Drug
1 trials
GI-102 subcutaneous (SC) Drug
1 trials
bevacizumab Drug
1 trials

US sites by state

Facility locations filed on Soft Tissue Sarcoma (STS) trials. A trial with sites in several states counts in each.

Ohio 1 trials
New York 1 trials
Minnesota 1 trials
Florida 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Soft Tissue Sarcoma (STS) page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Soft Tissue Sarcoma (STS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • GI Innovation sponsors the most Soft Tissue Sarcoma (STS) trials on record, review their full trial history before evaluating a specific study. See GI Innovation's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Soft Tissue Sarcoma (STS) condition card totals 1 registered trials; most-linked intervention paclitaxel; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.